These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35928818)

  • 21. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.
    Jiang Y; Ji Q; Long X; Wang P; Tu Z; Zhang X; Zhu X; Huang K; Li J
    Front Immunol; 2022; 13():810832. PubMed ID: 35265072
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Hu Z; Qu S
    Front Immunol; 2021; 12():683572. PubMed ID: 34267752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and clinical features of a potential immunotherapy target ELK3 in glioma.
    Xu H; Zhang L; Gao J; Wang J; Wang Y; Xiao D; Chai S
    Medicine (Baltimore); 2022 Jul; 101(30):e29544. PubMed ID: 35905257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GPR37 expression as a prognostic marker in gliomas: a bioinformatics-based analysis.
    Liang K; Guo Z; Zhang S; Chen D; Zou R; Weng Y; Peng C; Xu Z; Zhang J; Liu X; Pang X; Ji Y; Liao D; Lai M; Peng H; Ke Y; Wang Z; Wang Y
    Aging (Albany NY); 2023 Oct; 15(19):10146-10167. PubMed ID: 37837549
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Ma W; Zhang K; Bao Z; Jiang T; Zhang Y
    Front Immunol; 2021; 12():659659. PubMed ID: 33936093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
    Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
    Front Immunol; 2021; 12():628966. PubMed ID: 33664747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-promoting function of PIMREG in glioma by activating the β-catenin pathway.
    Wang D; Hu A; Peng H; Li D; Zhang L
    3 Biotech; 2021 Aug; 11(8):380. PubMed ID: 34458056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive Panel for Immunotherapy in Low-Grade Glioma.
    Lv Q; Zhang Z; Fu H; Li D; Liu Y; Sun Y; Wu M
    World Neurosurg; 2024 Mar; 183():e825-e837. PubMed ID: 38216032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
    Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
    Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas.
    Luo C; Liu Z; Ye W; Liu F
    Front Cell Dev Biol; 2021; 9():756005. PubMed ID: 34805164
    [No Abstract]   [Full Text] [Related]  

  • 31. CNPY4 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in gliomas.
    Li JW; Huang QR; Mo LG
    Medicine (Baltimore); 2022 Aug; 101(33):e30044. PubMed ID: 35984129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
    Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
    CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CD2-CD58 axis: A novel marker predicting poor prognosis in patients with low-grade gliomas and potential therapeutic approaches.
    Wu M; Chen Y; Hua G; Chunhui L
    Immun Inflamm Dis; 2023 Oct; 11(10):e1022. PubMed ID: 37904707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
    Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
    Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TUBA1C is a Prognostic Marker in Low-grade Glioma and Correlates with Immune Cell Infiltration in the Tumor Microenvironment.
    Zhu H; Hu X; Gu L; Jian Z; Li L; Hu S; Qiu S; Xiong X
    Front Genet; 2021; 12():759953. PubMed ID: 34721547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TGIF2 is a potential biomarker for diagnosis and prognosis of glioma.
    Zhang W; Zhang L; Dong H; Peng H
    Front Immunol; 2024; 15():1356833. PubMed ID: 38629068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-Cancer Analysis of PIMREG as a Biomarker for the Prognostic and Immunological Role.
    Zhu H; Hu X; Ye Y; Jian Z; Zhong Y; Gu L; Xiong X
    Front Genet; 2021; 12():687778. PubMed ID: 34594356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.
    Wu S; Miao K; Wang L; Ma Y; Wu X
    Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
    Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
    J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.